retatrutide fda status There are rumors that Trump got from Lilly before approval with their compassionate use program. This wouldn't clinically make sense as tirzepatide would be the better option to start with Retatrutide is an experimental weight-loss

Weeks 1-4 (2 mg dose) Weight loss is typically modest: 2-3% of body weight Appetite reduction may begin within the first week of injection Gastrointestinal side effects (nausea, decreased appetite) are most common during initial dosing For a person weighing 250 lbs (113 kg), this represents approximately 5-7 lbs (2-3 kg) Results may not be visually apparent to others at this stage Weeks 4-8 (4 mg dose) Weight loss accelerates as the dose increases Cumulative loss of approximately 4-5% of body weight Appetite suppression becomes more pronounced Clothing may begin to fit differently For a 250 lb individual: approximately 10-12 lbs (4-5 kg) lost Weeks 8-16 (6 mg to 9 mg) This is the period of most rapid dose escalation Cumulative loss of approximately 10-13% of body weight Results typically become noticeable to others Physical function improvements may become apparent (easier mobility, reduced joint discomfort) For a 250 lb individual: approximately 25-32 lbs (11-15 kg) lost Weeks 16-24 (reaching 12 mg maintenance) Full maintenance dose is reached around week 17 for the 12 mg regimen Weight loss rate is near its peak Cumulative loss of approximately 17-18% at 12 mg Significant changes in appearance, clothing size, and physical capabilities For a 250 lb individual: approximately 42-45 lbs (19-20 kg) lost Weeks 24-48 Weight loss continues at a gradually declining rate By week 48, mean loss of 24.2% at 12 mg (Phase 2 data) Cardiometabolic improvements (blood pressure, lipids, blood glucose) are well-established For a 250 lb individual: approximately 60 lbs (27 kg) lost Beyond 48 Weeks TRIUMPH-4 demonstrated continued weight loss to at least 68 weeks: -28.7% at 12 mg Whether weight loss continues beyond 68 weeks remains unknown

You May Be Eligible for Insurance Coverage for Zepbound or Wegovy Through MedLeanRx Many insurance plans now provide coverage for obesity treatment medications

Contact a healthcare provider right away if you experience: Sudden, severe abdominal pain that doesnt improve or radiates to your back Persistent vomiting or inability to keep fluids down Swelling in the face, hands, or legs Yellowing of the skin or eyes (jaundice) Severe dizziness, fainting, or confusion Blood in your stool or black, tar-like stools Severe mood changes, including depression or anxiety Signs of an allergic reaction, such as trouble breathing or facial swelling If youre ever unsure whether a symptom is serious, err on the side of caution and call your healthcare provider

What about food noise

Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis

Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al